Staar Surgical sees $630,838 in stock purchases by Broadwood Partners

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical (NASDAQ:STAA), a company known for its ophthalmic goods. Neal C. Bradsher, President of Broadwood Capital, Inc., which acts as the general partner of Broadwood Partners, is also noted as a significant owner, directly holding 25,900 shares. These moves come as part of Broadwood's broader investment strategy, reflecting their ongoing commitment to the medical technology sector. The company, with a market capitalization of $1.08 billion, remains profitable with a healthy gross margin of 79% and is scheduled to report its next earnings on February 19, 2025. The company, with a market capitalization of $1.08 billion, remains profitable with a healthy gross margin of 79% and is scheduled to report its next earnings on February 19, 2025.

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical, a company known for its ophthalmic goods. Neal C. Bradsher, President of Broadwood Capital, Inc., which acts as the general partner of Broadwood Partners, is also noted as a significant owner, directly holding 25,900 shares. These moves come as part of Broadwood's broader investment strategy, reflecting their ongoing commitment to the medical technology sector. The company, with a market capitalization of $1.08 billion, remains profitable with a healthy gross margin of 79% and is scheduled to report its next earnings on February 19, 2025.

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical, a company known for its ophthalmic goods. Neal C. Bradsher, President of Broadwood Capital, Inc., which acts as the general partner of Broadwood Partners, is also noted as a significant owner, directly holding 25,900 shares.

These moves come as part of Broadwood's broader investment strategy, reflecting their ongoing commitment to the medical technology sector.

In other recent news, STAAR Surgical Company reported a 10% year-over-year increase in its third-quarter net sales, reaching $88.6 million. This growth was primarily driven by a 10% rise in sales of its Implantable Collamer Lens ( ICL (TASE:ICL)) products. Despite macroeconomic challenges, particularly in China, the company maintained its fiscal year 2024 sales outlook, projecting revenues between $340 million and $345 million.

Mizuho (NYSE:MFG) and Stifel, two financial services firms, revised their stock price targets for STAAR Surgical, citing concerns over the market in China. Mizuho set a new target at $45.00, reduced from the previous figure of $50.00, but maintained its Outperform rating for the company. Stifel revised its stock price target from $42.00 to $38.00, maintaining a Buy rating on the stock.

In the healthcare sector, Piper Sandler analysts expressed optimism for several companies, including Procept BioRobotics, anticipating positive fiscal year outlooks. Procept BioRobotics reported robust revenue growth of 66% in the third quarter, totaling approximately $58.4 million, largely attributed to the company's Hydros units. The company also initiated a public offering of common stock valued at $175 million.

These are recent developments in the performance and projections of both STAAR Surgical Company and Procept BioRobotics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.